Viking Therapeutics, Inc. (VKTX)

Viking Therapeutics, Inc. is trading at $33.29, down 1.01% on the session. The 50 day average sits at $34.55 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 43.8, which reads as weak, and MACD is bearish crossover. Volume is below average.

The nearest support is around $30.80 with resistance near $34.85, so that band frames the current range. Average daily movement is roughly $1.55, or about 4.7% of the share price, which is what any stop placement has to allow for. The overall health score of 35 out of 100 combines a trend score of 32, momentum of 25 and a risk score of 52.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.